Zenagamtide, also known as amycretin and by the development code NN 9487, is an experimental weight loss drug being developed by Novo Nordisk. A single molecule acts as both a GLP-1 receptor agonist and an amylin receptor agonist, so it influences appetite regulation and metabolism together, which sets it apart from existing weight loss medications. It is built from two covalently linked peptides, analogs of GLP-1 and amylin. Unlike some competitors it can be taken by mouth, using salcaprozate sodium as a permeation enhancer, and a subcutaneous injection form is being developed in parallel.
Facts
Classification
Approval StatusInvestigational / Clinical Trial 1 Route of Administration Route of Administration Drug ClassGLP-1 and amylin receptor agonist (unimolecular) 2 Mechanism of ActionA single molecule that acts as an agonist of both the GLP-1 receptor and the amylin receptor 3 Connections
Sources
1. Zenagamtide (Wikipedia)
Lead section
It is under development by Novo Nordisk as a weight loss drug
Lead section [route-of-administration]
it can be delivered orally
Lead section [route-of-administration 2]
A subcutaneous injection formulation is being developed in parallel.
View the Source2. Efficacy and safety of once-daily oral zenagamtide in adults with type 2 diabetes (The Lancet, 2026)
Article title, drug description phraseQuote, Article title, drug description phrase
a novel unimolecular GLP-1 and amylin receptor agonist
3. Efficacy and safety of once-weekly subcutaneous zenagamtide in type 2 diabetes (The Lancet, 2026)
Article title, drug description phraseQuote, Article title, drug description phrase
a novel unimolecular GLP-1 and amylin receptor agonist
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.